Serologic antienzyme rate of Epstein-Barr virus DNase-specific neutralizing antibody segregates TNM classification in nasopharyngeal carcinoma

Journal of Clinical Oncology

Volumn 28, Issue 35, 2010, Pages 5202-5209

  Xu, Jie ^a   Wan, Xiang Bo ^a   Huang, Xue Fei ^a   Chan, K C Allen ^a   Hong, Ming Huang ^a   Wang, Li Hui ^a   Long, Zi Jie ^a   Liu, Qing ^a   Yan, Min ^a   Lo, Y M Dennis ^a   Zeng, Yi Xin ^a   Liu, Quentin ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEASE; ENZYME ANTIBODY;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; EPSTEIN BARR VIRUS; FEMALE; HUMAN; LOCAL FAILURE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DEOXYRIBONUCLEASES; DISEASE-FREE SURVIVAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; ROC CURVE;

EID: 79951873621     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.6552     Document Type: Article

References (54)

1. Wei WI, Sham JS: Nasopharyngeal carcinoma. Lancet 365:2041-2054, 2005 (Pubitemid 40812341)
2. Herrmann K, Niedobitek G: Epstein-Barr virus-associated carcinomas: Facts and fiction. J Pathol 199:140-145, 2003
3. Chang ET, Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15:1765-1777, 2006 (Pubitemid 44664247)
4. Lin JC, Jan JS, Hsu CY, et al: Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival. J Clin Oncol 21:631-637, 2003
5. Chan AT, Teo PM, Ngan RK, et al: Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20:2038-2044, 2002 (Pubitemid 34408793)
6. Langendijk JA, Leemans CR, Buter J, et al: The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: A meta-analysis of the published literature. J Clin Oncol 22:4604-4612, 2004 (Pubitemid 41185128)
7. Huncharek M, Kupelnick B: Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: Results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 25:219-223, 2002 (Pubitemid 34602538)
8. Kwong DL, Sham JS, Au GK, et al: Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: A factorial study. J Clin Oncol 22:2643-2653, 2004 (Pubitemid 41103752)
9. Lee AW, Lau WH, Tung SY, et al: Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23:6966-6975, 2005
10. Chua DT, Ma J, Sham JS, et al: Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: A pooled data analysis of two phase III trials. J Clin Oncol 23:1118-1124, 2005 (Pubitemid 46202267)
11. Yu KH, Leung SF, Tung SY, et al: Survival outcome of patients with nasopharyngeal carcinoma with first local failure: A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Head Neck 27:397-405, 2005 (Pubitemid 40593894)
12. Pathmanathan R, Prasad U, Sadler R, et al: Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 333:693-698, 1995
13. Chien YC, Chen JY, Liu MY, et al: Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 345:1877-1882, 2001
14. Chan AT, Lo YM, Zee B, et al: Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 94:1614-1619, 2002 (Pubitemid 35378726)
15. Lin JC, Chen KY, Wang WY, et al: Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: Relationship to distant metastasis and survival. J Clin Oncol 19:2607-2615, 2001 (Pubitemid 32441365)
16. Lin JC, Wang WY, Chen KY, et al: Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350:2461-2470, 2004 (Pubitemid 38736543)
17. Lin JC, Wang WY, Liang WM, et al: Long-term prognostic effects of plasma Epstein-Barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 68:1342-1348, 2007
18. Bortolin MT, Pratesi C, Dolcetti R, et al: Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Lett 233:247-254, 2006 (Pubitemid 43327380)
19. Mutirangura A, Pornthanakasem W, Theamboonlers A, et al: Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin Cancer Res 4:665-669, 1998 (Pubitemid 28193566)
20. Chang KP, Hsu CL, Chang YL, et al: Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: A possible alternative for primary screening of nasopharyngeal carcinoma. Oral Oncol 44:784-792, 2008
21. Cheng WM, Chan KH, Chen HL, et al: Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Int J Cancer 97:489-492, 2002 (Pubitemid 34027808)
22. Dardari R, Khyatti M, Benider A, et al: Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma. Int J Cancer 86:71-75, 2000 (Pubitemid 30133989)
23. De-Thé G, Geser A: Nasopharyngeal carcinoma: Recent studies and outlook for a viral etiology. Cancer Res 34:1196-1206, 1974
24. Tune CE, Liavaag PG, Freeman JL, et al: Nasopharyngeal brush biopsies and detection of nasopharyngeal cancer in a high-risk population. J Natl Cancer Inst 91:796-800, 1999 (Pubitemid 29239060)
25. Cheng YC, Chen JY, Glaser R, et al: Frequency and levels of antibodies to Epstein-Barr virus-specific DNase are elevated in patients with nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 77:6162-6165, 1980 (Pubitemid 11206362)
26. Chan KH, Gu YL, Ng F, et al: EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer 105:706-709, 2003 (Pubitemid 36687741)
27. Ayadi W, Karray-Hakim H, Feki L, et al: IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients. J Med Virol 81:1412-1421, 2009
28. Kondo S, Horikawa T, Takeshita H, et al: Diagnostic value of serum EBV-DNA quantification and antibody to viral capsid antigen in nasopharyngeal carcinoma patients. Cancer Sci 95:508-513, 2004 (Pubitemid 38832700)
29. Wang WY, Chien YC, Jan JS, et al: Consistent sequence variation of Epstein-Barr virus nuclear antigen 1 in primary tumor and peripheral blood cells of patients with nasopharyngeal carcinoma. Clin Cancer Res 8:2586-2590, 2002
30. Wong HL, Wang X, Chang RC, et al: Stable expression of EBERs in immortalized nasopharyngeal epithelial cells confers resistance to apoptotic stress. Mol Carcinog 44:92-101, 2005 (Pubitemid 41398204)
31. Zlobec I, Vuong T, Hayashi S, et al: A simple and reproducible scoring system for EGFR in colorectal cancer: Application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer 96:793-800, 2007 (Pubitemid 46376624)
32. Lo YM, Chan AT, Chan LY, et al: Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 60:6878-6881, 2000 (Pubitemid 32059157)
33. Chan SL, Mo FK, Johnson PJ, et al: New utility of an old marker: Serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 27:446-452, 2009
34. Marrero JA, Lok AS: Newer markers for hepatocellular carcinoma. Gastroenterology 127:S113-S119, 2004 (suppl 5) (Pubitemid 39423378)
35. Vickers AJ, Savage C, O'Brien MF, et al: Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27:398-403, 2009
36. Cheng YC, Chen JY, Hoffmann PJ, et al: Studies on the activity of DNase associated with the replication of the Epstein-Barr virus. Virology 100:334-338, 1980 (Pubitemid 10215477)
37. Zeng Y, Middeldorp J, Madjar JJ, et al: A major DNA binding protein encoded by BALF2 open reading frame of Epstein-Barr virus (EBV) forms a complex with other EBV DNA-binding proteins: DNAase, EA-D, and DNA polymerase. Virology 239:285-295, 1997 (Pubitemid 28105635)
38. Ma BB, King A, Lo YM, et al: Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66:714-720, 2006 (Pubitemid 44444855)
39. Al-Sarraf M, LeBlanc M, Giri PG, et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 16:1310-1317, 1998 (Pubitemid 28175745)
40. Hui EP, Ma BB, Leung SF, et al: Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 27:242-249, 2009
41. Wee J, Tan EH, Tai BC, et al: Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23:6730-6738, 2005 (Pubitemid 46190268)
42. Haddad R, Colevas AD, Tishler R, et al: Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: The Dana Farber Cancer Institute experience. Cancer 97:412-418, 2003 (Pubitemid 36133808)
43. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
44. Elser C, Siu LL, Winquist E, et al: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 25:3766-3773, 2007 (Pubitemid 47372619)
45. Comoli P, Pedrazzoli P, Maccario R, et al: Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23:8942-8949, 2005 (Pubitemid 46211479)
46. Chan AT, Tao Q, Robertson KD, et al: Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol 22:1373-1381, 2004 (Pubitemid 41103618)
47. Lee N, Xia P, Quivey JM, et al: Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int J Radiat Oncol Biol Phys 53:12-22, 2002 (Pubitemid 34465802)
48. Lee N, Harris J, Garden AS, et al: Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group phase II trial 0225. J Clin Oncol 27:3684-3690, 2009
49. Kam MK, Leung SF, Zee B, et al: Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25:4873-4879, 2007 (Pubitemid 350220416)
50. Lo YM, Chan LY, Chan AT, et al: Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 59:5452-5455, 1999 (Pubitemid 29526455)
51. Leung SF, Chan AT, Zee B, et al: Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 98:288-291, 2003 (Pubitemid 36828452)
52. Le QT, Jones CD, Yau TK, et al: A comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res 11:5700-5707, 2005
53. Chan KC, Zhang J, Chan AT, et al: Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 63:2028-2032, 2003 (Pubitemid 36538602)
54. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180-1184, 2005 (Pubitemid 41258223)